Table 3.

Other Janus kinase inhibitors evaluated in ulcerative colitis or Crohn's disease patients

Target	Therapeutic agent	Trial number	Phase	Status
Ulcerative colitis
Pan-JAK Inhibitor	Peficitiniba (ASP015K)	NCT01959282	Phase 2b induction therapy	No efficacy seen in moderate to severe UC and development was discontinued [85]
	Izencitinib (TD-1473)	NCT03758443	Phase 2b/3	Terminated early based on interim results
JAK-1 selective inhibitor	Ivarmacitinib (SHR0302)	NCT05181137	Phase 3	Recruiting
JAK-3 selective inhibitor	Ritlecitinib (PF-06651600)	Eudra CT2021-003702-42	Phase 3	Ongoing (positive results were reported in a Phase 2 study NCT02958865 [86])
TYK-2 selective inhibitor	Deucravacitinib (BMS-986165)	NCT04613518 and NCT 03934216	Phase 2 and open label	Recruiting
	Brepocitinib (PF-06651600)	NCT02958865	Phase 2b	Program discontinued despite positive Phase 2 study [86]
Crohn’s disease
Pan-JAK inhibitor	Izencitinib (TD-1473)	NCT03635112	Phase 2	Terminated early based on interim results
JAK-3 selective inhibitor	Ritlecitinib (PF-06651600)	NCT03395184	Phase 2a	Active, not recruiting
TYK-2 selective inhibitor	Deucravacitinib (BMS-986165)	NCT04877990	Open label	Recruiting
	Brepocitinib* (PF-06651600)	NCT03395184	Phase 2a	Active (unclear if will undergo further development)

JAK Janus kinase, TYK-2 tyrosine kinase 2, UC ulcerative colitis

^aThe development of peficitinib and brepocitinib in inflammatory bowel disease indications has now been discontinued